Status:
COMPLETED
ADHERE-S (NIS Brilique)
Lead Sponsor:
AstraZeneca
Conditions:
ACS (Acute Coronary Syndrome)
Eligibility:
All Genders
18+ years
Brief Summary
noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia
Eligibility Criteria
Inclusion
- ≥ 18 years of age
- diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively treated
- Patients already on treatment with ticagrelor at least for 1 month and no longer than 3 months prior to study initiation. Enrolment in this study must not be trigger for ticagrelor initiation.
- read and signed the Informed Consent Form
Exclusion
- Any contraindications as per approved SmPC of Brilique
- • Patients with life-threatening conditions which could disable patients to comply with scheduled visits and/or not able to fill in the patient questionnaires.
Key Trial Info
Start Date :
March 5 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 13 2019
Estimated Enrollment :
269 Patients enrolled
Trial Details
Trial ID
NCT03444012
Start Date
March 5 2018
End Date
August 13 2019
Last Update
August 7 2020
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
CHC Bezanijska Kosa
Belgrade, Serbia
2
CHC Zemun
Belgrade, Serbia
3
CHC Zvezdara
Belgrade, Serbia
4
Clinical Center of Serbia
Belgrade, Serbia